Navigation Links
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
Date:7/28/2009

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date.

The FDA did not identify safety concerns regarding INTUNIV in the Complete Response letter or request new clinical studies. Shire and the FDA will continue to work together to resolve the remaining labeling language over the next 4 to 8 weeks.

"Shire is confident that we will quickly come to agreement on the final product label and anticipates a launch in the fourth quarter as planned," said Mike Cola, President of Shire Specialty Pharmaceuticals. "When approved, INTUNIV will be the first selective alpha-2A receptor agonist for the treatment of ADHD, and will provide patients with an important new treatment option."

About INTUNIV

INTUNIV is being studied for the treatment of ADHD in children and adolescents aged 6 to 17 years. INTUNIV is a once-daily, extended release formulation of guanfacine, designed to provide steady delivery of drug throughout the day. INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex - an area of the brain that has been linked to ADHD.(4-6) Stimulation of the postsynaptic alpha-2A receptors is thought to strengthen working memory, reduce susceptibility to distraction, improve attention regulation, improve behavioral inhibition and enhance
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... Champions Oncology, Inc.  ("Champions" or  the ... a company engaged in the development of advanced technology ... of oncology drugs, has appointed Gary G. Gemignani to ... Chief Financial Officer. Joel Ackerman, the Company,s Chief Executive ...
... When it comes to breast cancer, a physician,s ability to ... treatment depends on the quality of information revealed through diagnostic ... most advanced technology in breast cancer detection with positron emission ... scanners in the Chicagoland area. Essentially, PEM is ...
Cached Medicine Technology:Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation 2Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation 3Palos Offers New Technology in the Fight Against Breast Cancer 2
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris ... college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio ... expand its reach and impact through innovative technologies and strategies. , “I am very ...
(Date:8/29/2015)... Church, VA (PRWEB) , ... August 30, 2015 ... ... **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... much more than a simple digital handwritten signature. , Clinical trial ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, ... improve the lives of patients, according to a newly published report. Surviving Mesothelioma ... the full article. , The authors of the new paper focus on ...
Breaking Medicine News(10 mins):Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2
... Hospitalar LFE 250SX and LFE 200SX to Target ... Bioscience (Nasdaq: PURE ) today announced ... (Lifebio), recently obtained national regulatory approval for its ... LFE 200SX" and "Desinfetante Hospitalar LFE 250SX," which ...
... City-Based Site Pulls Together Extensive State/Local Resources and ... A breakthrough Web solution for families, consumers and ... is now available to all New Yorkers. ... Behavioral Health ( www.nycnetworkofcare.org ) is an online ...
... Alta Bates Summit Medical Center will offer a free skin ... Street, Oakland, CA, 94609. This community cancer screening is supported ... Bay Area non-profit dedicated to changing the face of cancer. ... being diagnosed each year, skin cancer is the most common ...
... Service Corporation (Nasdaq: PRSC ) today announced ... million annual contract to operate a consumer-run adult mental ... contract is being funded through the state,s Mental Health ... home and community based delivery model is very much ...
... Choose Different Approaches, Yet Face Hurdles in Light ... HealthLeaders-InterStudy NASHVILLE, Tenn., Feb. 19 HealthLeaders-InterStudy, ... reports that significant state Medicaid reform efforts in ... in light of the nation,s economic downturn, particularly ...
... 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; ... results for the fourth quarter ending December 31, 2008 and ... 2009. Unless specified otherwise, all amounts are in U.S. dollars ... pivotal year for us as we concluded a series of ...
Cached Medicine News:Health News:PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants 2Health News:PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants 3Health News:PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants 4Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 3Health News:Lazarex Cancer Foundation Sponsors Free Community Skin Cancer Screening at Alta Bates Summit Medical Center 2Health News:Providence Service Corporation California Subsidiary Awarded $1.5 Million Contract Under State's Mental Health Services Act 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 4Health News:QLT Announces Fourth Quarter and Year End 2008 Results 5Health News:QLT Announces Fourth Quarter and Year End 2008 Results 6Health News:QLT Announces Fourth Quarter and Year End 2008 Results 7Health News:QLT Announces Fourth Quarter and Year End 2008 Results 8Health News:QLT Announces Fourth Quarter and Year End 2008 Results 9Health News:QLT Announces Fourth Quarter and Year End 2008 Results 10Health News:QLT Announces Fourth Quarter and Year End 2008 Results 11Health News:QLT Announces Fourth Quarter and Year End 2008 Results 12Health News:QLT Announces Fourth Quarter and Year End 2008 Results 13Health News:QLT Announces Fourth Quarter and Year End 2008 Results 14Health News:QLT Announces Fourth Quarter and Year End 2008 Results 15Health News:QLT Announces Fourth Quarter and Year End 2008 Results 16Health News:QLT Announces Fourth Quarter and Year End 2008 Results 17Health News:QLT Announces Fourth Quarter and Year End 2008 Results 18Health News:QLT Announces Fourth Quarter and Year End 2008 Results 19
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: